A number of other research analysts also recently commented on the stock. Credit Suisse Group initiated coverage on shares of Athenex in a research report on Monday. They set an outperform rating and a $25.00 target price on the stock. Royal Bank Of Canada assumed coverage on shares of Athenex in a report on Thursday, September 14th. They issued an outperform rating and a $35.00 price target on the stock. Finally, Deutsche Bank AG assumed coverage on shares of Athenex in a research note on Monday, July 10th. They issued a buy rating and a $20.00 target price for the company.
Athenex (NASDAQ ATNX) opened at 17.50 on Tuesday. The stock’s market cap is $998.60 million. Athenex has a 52-week low of $11.21 and a 52-week high of $20.79. The firm has a 50 day moving average of $16.18 and a 200-day moving average of $16.51.
Athenex (NASDAQ:ATNX) last released its earnings results on Monday, August 14th. The company reported ($0.88) earnings per share (EPS) for the quarter. The firm had revenue of $4.60 million for the quarter. Equities analysts anticipate that Athenex will post ($1.76) earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp purchased a new stake in shares of Athenex during the second quarter worth $240,000. Tudor Investment Corp ET AL acquired a new position in shares of Athenex during the 2nd quarter valued at about $320,000. Goldman Sachs Group Inc. acquired a new position in shares of Athenex during the 2nd quarter valued at about $601,000. California Public Employees Retirement System acquired a new position in shares of Athenex during the 2nd quarter valued at about $800,000. Finally, Vanguard Group Inc. acquired a new position in shares of Athenex during the 2nd quarter valued at about $800,000. 0.88% of the stock is owned by institutional investors and hedge funds.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.